Trial · NCT06670222
Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)
NCT06670222, Phase 1, Recruiting, Groupe Francophone des Myelodysplasies
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS). Trials, record NCT06670222. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06670222
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)
- NCT number
- NCT06670222
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 24 participants, estimated
- Lead sponsor
- Groupe Francophone des Myelodysplasies
- Conditions
- Low-risk Myelodysplastic Syndromes
- Interventions
- Arsenic Trioxide (ATO)
- First posted
- 2024-11-01
- Last updated
- 2026-09-10
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To determine the dose-limiting toxicity (DLT) of oral Arsenic (ATO) | At the end of cycle 1 (each cycle is 28 days) | Dose-limiting toxicity will be defined by the occurrence during the first treatment cycle of any of the following toxicities related to the trial drug (oral ATO): * Non-hematological toxicity of grade ≥ 3 * Hematological toxicity of grade ≥ 4 corresponding to a decrease of 50% or more of absolute neutrophil count (ANC) or platelet count from baseline or lower limit (if baseline was above normal), without recovery at D42 of the first cycle. |
| Secondary | To determine safety profile | Through study completion, an average of 2 years | Toxicities measured according to CTCAE (Common Terminology Criteria for Adverse Events) |
| Secondary | Pharmacokinetics | At the end of cycle 1 (each cycle is 28 days) | Measurement of the peak plasma concentration (Cmax) of oral ATO |
| Secondary | Pharmacokinetics | At the end of cycle 1 (each cycle is 28 days) | Measurement of area under the plasma concentration versus time curve (AUC) for oral ATO |
| Secondary | Pharmacokinetics | At the end of cycle 1 (each cycle is 28 days) | Measurement of the residual concentration (Cmin) of oral ATO |
| Secondary | Efficacy | At the end of cycle 3 (each cycle is 28 days) | Response rate (Complete Response + Partial Response + stable disease with hematological improvement according to IWG (International Working Group) 2018 criteria) |
| Secondary | Response duration | Through study completion, an average of 2 years | Response duration measured from date of objective response to date of relapse or progression (or date of last news in absence of event) |
| Secondary | Progression-free survival | Through study completion, an average of 2 years | Rate and time to transformation to high-risk myelodysplastic syndrome (MDS) or Acute Myeloid Leukemia (AML) |
| Secondary | Overall survival | Through study completion, an average of 2 years | Overall survival from date of inclusion to death or date of last news |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06670222
GET https://conductscience.org/api/trials/v1/NCT06670222/registered